Lisa Jarvis: A sickle cell breakthrough is here. Now the har

The approval of Casgevy, Vertex Pharmaceuticals Inc. and Crispr Therapeutics Inc.’s gene therapy for sickle cell disease, is a transformative moment in medicine. Not only is it the first Crispr-based

Related Keywords

, Crispr Therapeutics Inc , Drug Administration , Vertex Pharmaceuticals Inc , Vertex Pharmaceuticals , Crispr Therapeutics , Bluebird Bio , Business And Commerce , Government Regulatory Actions , Business Regulation , Ealth And Wellness , Drug And Device Approval Process , Blood Disorders , Edical Conditions And Diseases , Drug Testing And Approval Process , Egulatory Drug Approval , Edicinal Drugs , Ene And Genetic Therapy , Medical And Pharmaceutical Regulation , Sickle Cell Disease , Reatments And Therapies , Rading Impact Ice Codes Important Corporate Events , Editorial Opinion , Olitics And Government , Overnment Agencies Us , Food And Drug Administration , Department Of Health And Human Services , Government Regulation , Ngene Therapeutics , Biopharmaceuticals , Biotechnology , Pharmaceuticals , North America , United States , Americas , Massachusetts ,